{"title":"Generating functionally stable and antigen-specific Treg cells from effector T cells for cell therapy of inflammatory diseases","authors":"Norihisa Mikami, Ryoji Kawakami, Atsushi Sugimoto, Masaya Arai, Shimon Sakaguchi","doi":"10.1126/scitranslmed.adr6049","DOIUrl":null,"url":null,"abstract":"<div >One strategy for antigen-specific immunosuppression is to convert antigen-specific conventional T (T<sub>conv</sub>) cells into Foxp3<sup>+</sup> regulatory T (T<sub>reg</sub>) cells that are as stably suppressive as naturally occurring T<sub>reg</sub> (nT<sub>reg</sub>) cells. To achieve the conversion in vitro for mice and humans, we induced high Foxp3 expression in antigen- and interleukin-2 (IL-2)–stimulated T<sub>conv</sub> cells by CDK8/19 inhibition. We further established T<sub>reg</sub> cell–specific epigenetic changes by depriving CD28 costimulation during in vitro T<sub>reg</sub> cell induction to specifically promote the expression of T<sub>reg</sub> cell signature genes, especially <i>Foxp3</i>. Repeating this process, with intermittent resting cultures containing IL-2 only, enabled efficient conversion of naïve as well as effector/memory CD4<sup>+</sup> T<sub>conv</sub> cells, including T helper 1 (T<sub>H</sub>1), T<sub>H</sub>2, and T<sub>H</sub>17 cells, into Foxp3<sup>+</sup> T<sub>reg</sub> cells. These induced T<sub>reg</sub> (iT<sub>reg</sub>) cells were similar to nT<sub>reg</sub> cells in transcription and epigenetic modification and were functionally and phenotypically stable in vivo. Moreover, they effectively suppressed inflammatory bowel disease and graft-versus-host disease in mouse models. Adoptive cell therapy with such effector/memory T<sub>conv</sub> cell–derived, functionally stable, iT<sub>reg</sub> cells may represent a strategy to achieve antigen- and disease-specific treatment of immunological diseases.</div>","PeriodicalId":21580,"journal":{"name":"Science Translational Medicine","volume":"17 821","pages":""},"PeriodicalIF":14.6000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Science Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.science.org/doi/10.1126/scitranslmed.adr6049","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
One strategy for antigen-specific immunosuppression is to convert antigen-specific conventional T (Tconv) cells into Foxp3+ regulatory T (Treg) cells that are as stably suppressive as naturally occurring Treg (nTreg) cells. To achieve the conversion in vitro for mice and humans, we induced high Foxp3 expression in antigen- and interleukin-2 (IL-2)–stimulated Tconv cells by CDK8/19 inhibition. We further established Treg cell–specific epigenetic changes by depriving CD28 costimulation during in vitro Treg cell induction to specifically promote the expression of Treg cell signature genes, especially Foxp3. Repeating this process, with intermittent resting cultures containing IL-2 only, enabled efficient conversion of naïve as well as effector/memory CD4+ Tconv cells, including T helper 1 (TH1), TH2, and TH17 cells, into Foxp3+ Treg cells. These induced Treg (iTreg) cells were similar to nTreg cells in transcription and epigenetic modification and were functionally and phenotypically stable in vivo. Moreover, they effectively suppressed inflammatory bowel disease and graft-versus-host disease in mouse models. Adoptive cell therapy with such effector/memory Tconv cell–derived, functionally stable, iTreg cells may represent a strategy to achieve antigen- and disease-specific treatment of immunological diseases.
期刊介绍:
Science Translational Medicine is an online journal that focuses on publishing research at the intersection of science, engineering, and medicine. The goal of the journal is to promote human health by providing a platform for researchers from various disciplines to communicate their latest advancements in biomedical, translational, and clinical research.
The journal aims to address the slow translation of scientific knowledge into effective treatments and health measures. It publishes articles that fill the knowledge gaps between preclinical research and medical applications, with a focus on accelerating the translation of knowledge into new ways of preventing, diagnosing, and treating human diseases.
The scope of Science Translational Medicine includes various areas such as cardiovascular disease, immunology/vaccines, metabolism/diabetes/obesity, neuroscience/neurology/psychiatry, cancer, infectious diseases, policy, behavior, bioengineering, chemical genomics/drug discovery, imaging, applied physical sciences, medical nanotechnology, drug delivery, biomarkers, gene therapy/regenerative medicine, toxicology and pharmacokinetics, data mining, cell culture, animal and human studies, medical informatics, and other interdisciplinary approaches to medicine.
The target audience of the journal includes researchers and management in academia, government, and the biotechnology and pharmaceutical industries. It is also relevant to physician scientists, regulators, policy makers, investors, business developers, and funding agencies.